Dynavax Technologies Corp.

Find Ratings Reports
DVAX : NASDAQ : Health Technology
$17.25 up 0.025 | 0.15%
Today's Range: 16.85 - 18.5
Avg. Daily Volume: 1339500.0
02/20/18 - 4:00 PM ET

Financial Analysis


DYNAVAX TECHNOLOGIES CORP's gross profit margin for the third quarter of its fiscal year 2017 has significantly decreased when compared to the same period a year ago. Even though sales decreased, the net income has increased. DYNAVAX TECHNOLOGIES CORP is extremely liquid. Currently, the Quick Ratio is 14.93 which clearly shows the ability to cover any short-term cash needs. DVAX managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.

At the same time, stockholders' equity ("net worth") has greatly increased by 88.81% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q3 FY17 Q3 FY16
Net Sales ($mil)0.050.16
EBITDA ($mil)-21.61-34.21
EBIT ($mil)-22.39-34.84
Net Income ($mil)-22.13-34.69


Balance Sheet Q3 FY17 Q3 FY16
Cash & Equiv. ($mil)191.68109.55
Total Assets ($mil)217.83139.3
Total Debt ($mil)0.00.0
Equity ($mil)204.43108.27


Profitability Q3 FY17 Q3 FY16
Gross Profit Margin-40771.7-21117.28
EBITDA Margin-40771.69-21117.28
Operating Margin-42247.17-21504.94
Sales Turnover0.030.03
Return on Assets-41.07-84.39
Return on Equity-43.76-108.58
Debt Q3 FY17 Q3 FY16
Current Ratio15.293.85
Debt/Capital0.00.0
Interest Expense0.00.0
Interest Coverage0.00.0


Share Data Q3 FY17 Q3 FY16
Shares outstanding (mil)60.5938.53
Div / share0.00.0
EPS-0.38-0.9
Book value / share3.372.81
Institutional Own % n/a n/a
Avg Daily Volume1382259.01872916.0

Valuation


SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 5.05 indicates a significant premium versus the S&P 500 average of 3.26 and a significant discount versus the industry average of 15.63. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. The valuation analysis reveals that, DYNAVAX TECHNOLOGIES CORP seems to be trading at a premium to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
DVAX NM Peers 46.82   DVAX NM Peers 41.91

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

DVAX's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

DVAX's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
DVAX NM Peers 28.60   DVAX NA Peers 0.35

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

DVAX's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
DVAX 5.05 Peers 15.63   DVAX 36.07 Peers 2.21

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

DVAX is trading at a significant discount to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

DVAX is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
DVAX 135.92 Peers 87.22   DVAX 71.28 Peers 120.94

Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

DVAX is trading at a significant premium to its industry.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

DVAX significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades